🔗 Share this article Patients Stopping Weight-Loss Jabs Gain Back Weight Far More Rapidly Than Those on Conventional Diets Weight management often requires ongoing approaches. Fresh analysis indicates that patients who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who stop traditional diet and exercise programs. Published data in a prominent medical journal shows that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation. "Users buying such drugs need to be cognizant of the potential of quick weight regain when the treatment ends," stated expert Dr. Susan Jebb. Such speed of regain implies a return to pre-treatment weight within about 18 months. Weighing Therapies The study, which reviewed dozens of studies involving thousands of participants, contrasted the results of the injectable medications with conventional dieting. Researchers emphasize that people who lose weight through lifestyle changes alone usually see a slower creep back—perhaps 0.1 kg a month—post-intervention. Explaining the Fast Regain Doctors believe the way of the drugs is key to understanding the heightened rebound. GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate appetite. "Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication means hunger is no longer kept in check, making overeating a significant risk." A Chronic Disease? The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. Professionals say that, given the significant potential of weight regain, the treatment is often life-long. This opinion is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like diabetes. User Accounts Users who have discontinued the medication report a intense resurgence of cravings. "I experienced a switch activating and you become ravenous," described one woman. This difficulty is worsened if users have not established lasting dietary or behavioural changes during treatment. Widespread Adoption Survey data indicate that millions of people in the UK have tried these injections in the past year, with desire being substantial. Adoption is greater among women compared to men. The 40s and 50s demographic shows the greatest usage rates. A large proportion obtain the medications through private prescriptions rather than the NHS. Ultimately, researchers stress that while these medications are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on combined lifestyle management.
Weight management often requires ongoing approaches. Fresh analysis indicates that patients who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who stop traditional diet and exercise programs. Published data in a prominent medical journal shows that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation. "Users buying such drugs need to be cognizant of the potential of quick weight regain when the treatment ends," stated expert Dr. Susan Jebb. Such speed of regain implies a return to pre-treatment weight within about 18 months. Weighing Therapies The study, which reviewed dozens of studies involving thousands of participants, contrasted the results of the injectable medications with conventional dieting. Researchers emphasize that people who lose weight through lifestyle changes alone usually see a slower creep back—perhaps 0.1 kg a month—post-intervention. Explaining the Fast Regain Doctors believe the way of the drugs is key to understanding the heightened rebound. GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate appetite. "Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication means hunger is no longer kept in check, making overeating a significant risk." A Chronic Disease? The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. Professionals say that, given the significant potential of weight regain, the treatment is often life-long. This opinion is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like diabetes. User Accounts Users who have discontinued the medication report a intense resurgence of cravings. "I experienced a switch activating and you become ravenous," described one woman. This difficulty is worsened if users have not established lasting dietary or behavioural changes during treatment. Widespread Adoption Survey data indicate that millions of people in the UK have tried these injections in the past year, with desire being substantial. Adoption is greater among women compared to men. The 40s and 50s demographic shows the greatest usage rates. A large proportion obtain the medications through private prescriptions rather than the NHS. Ultimately, researchers stress that while these medications are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on combined lifestyle management.